While generative AI is a relatively new household term, drug discovery company Insilico Medicine has been using it for years to develop new therapies for debilitating diseases. The company’s early bet on deep learning is bearing fruit — a drug candidate discovered using its AI platform is now entering Phase 2 clinical trials to treat Read article >